The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial

BACKGROUND: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been questioned and remains undetermined in the immuno-oncology era. Results from the two randomized trials, CARMENA and SURTIME, have questioned the role and timing of the surgery in these patients, however, these trials have only used the targeted therapy, sunitinib. With the advent of more effective systemic therapies including immune checkpoint inhibitors (ICIs), the role of surgical therapy should be reexamined. RATIONALE: The therapeutic effects of ICIs have demonstrated

Trial Details

NCT ID
NCT05753839
Phase
NA
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cytoreductive nephrectomy±metastasectomy
  • Human-derived materials sampling
Locations (sample)
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Yongin-si, South Korea|37.29686,127.08042

Key Eligibility Criteria

  • Core needle biopsy proven metastatic renal cell carcinoma - clear cell histologic subtypes only acceptable.
  • Synchronous metastatic renal cell carcinoma with the primary tumor present in the kidney.
  • Patient must be willing to provide their human-derived materials.
  • Signed written informed consent obtained prior to any study specific procedures.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →